News
May 1, 2020
Obsidian Therapeutics Develops and Shares Safe Workplace Productivity Solution in Response to COVID19 Implementation has enabled Obsidian to remain on track to meet development targets, while […]
March 3, 2020
Obsidian Therapeutics Appoints Anders Götzsche to Board of Directors March 3, 2020, 07:00 AM Eastern Standard Time CAMBRIDGE, Mass., March 3, 2020 – Obsidian Therapeutics, a biotechnology […]
February 5, 2020
Obsidian Therapeutics Announces Formation of Scientific Advisory Board Members will help to guide the development strategy of existing pipeline as well as identify innovative applications for […]
November 12, 2019
Obsidian Therapeutics Announces Expansion of Leadership Team Additions support Obsidian’s active program development, operational build-out and ongoing regulatory discussions Nov. 12, 2019, 08:00 AM Eastern Standard […]
September 24, 2019
Obsidian Therapeutics Appoints Erin Boyer as Vice President, Human Resources Sept. 24, 2019 07:30 AM Eastern Daylight Time CAMBRIDGE, Mass., Sept. 24, 2019 – Obsidian Therapeutics, a […]
July 25, 2019
Obsidian Therapeutics Announces Strengthening of Executive Leadership Team Expanded Leadership Supports Company Evolution into Development-Stage Biotechnology Company using cytoDRiVE™ Technology to Regulate Cell and Gene Therapies […]
April 18, 2019
Obsidian Therapeutics Announces Leadership Transition and Appoints Paul K. Wotton, Ph.D., as Chief Executive Officer Experienced CEO brings expertise in product development, cell and gene therapies, […]
January 18, 2019
Obsidian Therapeutics Announces Strategic Collaboration with Celgene to Develop Novel Cell Therapies with Tunable Immunomodulatory Factors, Opening Potential for CAR-T and Other Cellular Medicines in New […]
December 6, 2017
Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy Products Financing led by GV to focus on lead programs for […]